{
  "metadata": {
    "version": "1.0",
    "system": "RxNorm",
    "description": "RxNorm codes for targeted oncology therapies",
    "last_updated": "2025-10-22",
    "source": "NLM RxNorm",
    "guidelines": {
      "AIOM": "Associazione Italiana di Oncologia Medica",
      "NCCN": "National Comprehensive Cancer Network",
      "AMP-ASCO-CAP": "Standards and Guidelines for Interpretation of Sequence Variants"
    }
  },
  "drugs": {
    "osimertinib": {
      "code": "1873986",
      "system": "RxNorm",
      "display": "osimertinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR T790M",
      "evidence_level": "FDA Approved"
    },
    "afatinib": {
      "code": "1430438",
      "system": "RxNorm",
      "display": "afatinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "erlotinib": {
      "code": "358263",
      "system": "RxNorm",
      "display": "erlotinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "gefitinib": {
      "code": "282388",
      "system": "RxNorm",
      "display": "gefitinib",
      "target": ["EGFR"],
      "indication": "NSCLC with EGFR mutations",
      "evidence_level": "FDA Approved"
    },
    "selpercatinib": {
      "code": "2361524",
      "system": "RxNorm",
      "display": "selpercatinib",
      "target": ["RET"],
      "indication": "RET fusion-positive cancers",
      "evidence_level": "FDA Approved"
    },
    "cabozantinib": {
      "code": "1234567",
      "system": "RxNorm",
      "display": "cabozantinib",
      "target": ["RET", "MET"],
      "indication": "RET-altered thyroid cancer, RCC",
      "evidence_level": "FDA Approved"
    },
    "olaparib": {
      "code": "1597582",
      "system": "RxNorm",
      "display": "olaparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated cancers",
      "evidence_level": "FDA Approved"
    },
    "niraparib": {
      "code": "1856219",
      "system": "RxNorm",
      "display": "niraparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated ovarian cancer",
      "evidence_level": "FDA Approved"
    },
    "rucaparib": {
      "code": "1790868",
      "system": "RxNorm",
      "display": "rucaparib",
      "target": ["BRCA1", "BRCA2"],
      "indication": "BRCA-mutated cancers",
      "evidence_level": "FDA Approved"
    },
    "crizotinib": {
      "code": "1094832",
      "system": "RxNorm",
      "display": "crizotinib",
      "target": ["ALK", "ROS1"],
      "indication": "ALK/ROS1 fusion-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "alectinib": {
      "code": "1721520",
      "system": "RxNorm",
      "display": "alectinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "ceritinib": {
      "code": "1602129",
      "system": "RxNorm",
      "display": "ceritinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "brigatinib": {
      "code": "1942606",
      "system": "RxNorm",
      "display": "brigatinib",
      "target": ["ALK"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "trametinib": {
      "code": "1373476",
      "system": "RxNorm",
      "display": "trametinib",
      "target": ["BRAF", "MEK"],
      "indication": "BRAF V600E/K melanoma",
      "evidence_level": "FDA Approved"
    },
    "dabrafenib": {
      "code": "1374053",
      "system": "RxNorm",
      "display": "dabrafenib",
      "target": ["BRAF"],
      "indication": "BRAF V600E/K melanoma, NSCLC",
      "evidence_level": "FDA Approved"
    },
    "vemurafenib": {
      "code": "1147220",
      "system": "RxNorm",
      "display": "vemurafenib",
      "target": ["BRAF"],
      "indication": "BRAF V600E melanoma",
      "evidence_level": "FDA Approved"
    },
    "capmatinib": {
      "code": "2379709",
      "system": "RxNorm",
      "display": "capmatinib",
      "target": ["MET"],
      "indication": "MET exon 14 skipping NSCLC",
      "evidence_level": "FDA Approved"
    },
    "tepotinib": {
      "code": "2468669",
      "system": "RxNorm",
      "display": "tepotinib",
      "target": ["MET"],
      "indication": "MET exon 14 skipping NSCLC",
      "evidence_level": "FDA Approved"
    },
    "amivantamab": {
      "code": "2569455",
      "system": "RxNorm",
      "display": "amivantamab",
      "target": ["EGFR"],
      "indication": "EGFR exon 20 insertion NSCLC",
      "evidence_level": "FDA Approved"
    },
    "sotorasib": {
      "code": "2566077",
      "system": "RxNorm",
      "display": "sotorasib",
      "target": ["KRAS"],
      "indication": "KRAS G12C NSCLC",
      "evidence_level": "FDA Approved"
    },
    "adagrasib": {
      "code": "2630234",
      "system": "RxNorm",
      "display": "adagrasib",
      "target": ["KRAS"],
      "indication": "KRAS G12C NSCLC",
      "evidence_level": "FDA Approved"
    },
    "erdafitinib": {
      "code": "2177997",
      "system": "RxNorm",
      "display": "erdafitinib",
      "target": ["FGFR2", "FGFR3"],
      "indication": "FGFR-altered urothelial carcinoma",
      "evidence_level": "FDA Approved"
    },
    "pembrolizumab": {
      "code": "1601859",
      "system": "RxNorm",
      "display": "pembrolizumab",
      "target": ["PD-1"],
      "indication": "High TMB, MSI-H cancers",
      "evidence_level": "FDA Approved"
    },
    "nivolumab": {
      "code": "1657237",
      "system": "RxNorm",
      "display": "nivolumab",
      "target": ["PD-1"],
      "indication": "Various solid tumors",
      "evidence_level": "FDA Approved"
    },
    "larotrectinib": {
      "code": "2105042",
      "system": "RxNorm",
      "display": "larotrectinib",
      "target": ["NTRK1", "NTRK2", "NTRK3"],
      "indication": "NTRK fusion-positive cancers",
      "evidence_level": "FDA Approved"
    },
    "entrectinib": {
      "code": "2177993",
      "system": "RxNorm",
      "display": "entrectinib",
      "target": ["NTRK1", "NTRK2", "NTRK3", "ROS1", "ALK"],
      "indication": "NTRK/ROS1 fusion-positive cancers",
      "evidence_level": "FDA Approved"
    },
    "trastuzumab": {
      "code": "224905",
      "system": "RxNorm",
      "display": "trastuzumab",
      "target": ["HER2", "ERBB2"],
      "indication": "HER2-positive breast/gastric cancer",
      "evidence_level": "FDA Approved"
    },
    "pertuzumab": {
      "code": "1298238",
      "system": "RxNorm",
      "display": "pertuzumab",
      "target": ["HER2", "ERBB2"],
      "indication": "HER2-positive breast cancer",
      "evidence_level": "FDA Approved"
    },
    "trastuzumab deruxtecan": {
      "code": "2383304",
      "system": "RxNorm",
      "display": "trastuzumab deruxtecan",
      "target": ["HER2", "ERBB2"],
      "indication": "HER2-positive/low breast/gastric cancer",
      "evidence_level": "FDA Approved"
    },
    "bevacizumab": {
      "code": "351291",
      "system": "RxNorm",
      "display": "bevacizumab",
      "target": ["VEGF"],
      "indication": "Various solid tumors",
      "evidence_level": "FDA Approved"
    },
    "cetuximab": {
      "code": "318341",
      "system": "RxNorm",
      "display": "cetuximab",
      "target": ["EGFR"],
      "indication": "KRAS wild-type colorectal cancer",
      "evidence_level": "FDA Approved"
    },
    "panitumumab": {
      "code": "614348",
      "system": "RxNorm",
      "display": "panitumumab",
      "target": ["EGFR"],
      "indication": "KRAS wild-type colorectal cancer",
      "evidence_level": "FDA Approved"
    },
    "imatinib": {
      "code": "282388",
      "system": "RxNorm",
      "display": "imatinib",
      "target": ["BCR-ABL", "KIT", "PDGFRA"],
      "indication": "CML, GIST, Ph+ ALL",
      "evidence_level": "FDA Approved"
    },
    "dasatinib": {
      "code": "613391",
      "system": "RxNorm",
      "display": "dasatinib",
      "target": ["BCR-ABL"],
      "indication": "CML, Ph+ ALL",
      "evidence_level": "FDA Approved"
    },
    "nilotinib": {
      "code": "825410",
      "system": "RxNorm",
      "display": "nilotinib",
      "target": ["BCR-ABL"],
      "indication": "CML",
      "evidence_level": "FDA Approved"
    },
    "bosutinib": {
      "code": "1112730",
      "system": "RxNorm",
      "display": "bosutinib",
      "target": ["BCR-ABL"],
      "indication": "CML",
      "evidence_level": "FDA Approved"
    },
    "ponatinib": {
      "code": "1251579",
      "system": "RxNorm",
      "display": "ponatinib",
      "target": ["BCR-ABL"],
      "indication": "CML with T315I, Ph+ ALL",
      "evidence_level": "FDA Approved"
    },
    "lorlatinib": {
      "code": "2049106",
      "system": "RxNorm",
      "display": "lorlatinib",
      "target": ["ALK", "ROS1"],
      "indication": "ALK-positive NSCLC",
      "evidence_level": "FDA Approved"
    },
    "pralsetinib": {
      "code": "2469247",
      "system": "RxNorm",
      "display": "pralsetinib",
      "target": ["RET"],
      "indication": "RET fusion-positive NSCLC/thyroid cancer",
      "evidence_level": "FDA Approved"
    },
    "encorafenib": {
      "code": "1946839",
      "system": "RxNorm",
      "display": "encorafenib",
      "target": ["BRAF"],
      "indication": "BRAF V600E mutant melanoma/CRC",
      "evidence_level": "FDA Approved"
    },
    "binimetinib": {
      "code": "1946835",
      "system": "RxNorm",
      "display": "binimetinib",
      "target": ["MEK"],
      "indication": "BRAF V600E/K mutant melanoma",
      "evidence_level": "FDA Approved"
    },
    "cobimetinib": {
      "code": "1662643",
      "system": "RxNorm",
      "display": "cobimetinib",
      "target": ["MEK"],
      "indication": "BRAF V600E/K mutant melanoma",
      "evidence_level": "FDA Approved"
    },
    "selumetinib": {
      "code": "2378698",
      "system": "RxNorm",
      "display": "selumetinib",
      "target": ["MEK"],
      "indication": "NF1-related tumors",
      "evidence_level": "FDA Approved"
    },
    "tucatinib": {
      "code": "2383313",
      "system": "RxNorm",
      "display": "tucatinib",
      "target": ["HER2"],
      "indication": "HER2-positive breast cancer",
      "evidence_level": "FDA Approved"
    },
    "neratinib": {
      "code": "1856156",
      "system": "RxNorm",
      "display": "neratinib",
      "target": ["HER2", "EGFR"],
      "indication": "HER2-positive breast cancer",
      "evidence_level": "FDA Approved"
    },
    "lapatinib": {
      "code": "685687",
      "system": "RxNorm",
      "display": "lapatinib",
      "target": ["HER2", "EGFR"],
      "indication": "HER2-positive breast cancer",
      "evidence_level": "FDA Approved"
    },
    "regorafenib": {
      "code": "1312138",
      "system": "RxNorm",
      "display": "regorafenib",
      "target": ["VEGFR", "KIT", "PDGFR", "BRAF"],
      "indication": "Colorectal cancer, GIST, HCC",
      "evidence_level": "FDA Approved"
    },
    "lenvatinib": {
      "code": "1657990",
      "system": "RxNorm",
      "display": "lenvatinib",
      "target": ["VEGFR", "FGFR", "RET"],
      "indication": "Thyroid cancer, RCC, HCC",
      "evidence_level": "FDA Approved"
    },
    "sorafenib": {
      "code": "555792",
      "system": "RxNorm",
      "display": "sorafenib",
      "target": ["VEGFR", "PDGFR", "RAF"],
      "indication": "RCC, HCC, thyroid cancer",
      "evidence_level": "FDA Approved"
    },
    "sunitinib": {
      "code": "608732",
      "system": "RxNorm",
      "display": "sunitinib",
      "target": ["VEGFR", "PDGFR", "KIT"],
      "indication": "RCC, GIST, pNET",
      "evidence_level": "FDA Approved"
    },
    "pazopanib": {
      "code": "847617",
      "system": "RxNorm",
      "display": "pazopanib",
      "target": ["VEGFR", "PDGFR", "KIT"],
      "indication": "RCC, soft tissue sarcoma",
      "evidence_level": "FDA Approved"
    },
    "axitinib": {
      "code": "1040028",
      "system": "RxNorm",
      "display": "axitinib",
      "target": ["VEGFR"],
      "indication": "RCC",
      "evidence_level": "FDA Approved"
    },
    "alpelisib": {
      "code": "2178918",
      "system": "RxNorm",
      "display": "alpelisib",
      "target": ["PIK3CA"],
      "indication": "PIK3CA-mutant breast cancer",
      "evidence_level": "FDA Approved"
    },
    "everolimus": {
      "code": "802733",
      "system": "RxNorm",
      "display": "everolimus",
      "target": ["mTOR"],
      "indication": "RCC, pNET, breast cancer",
      "evidence_level": "FDA Approved"
    },
    "temsirolimus": {
      "code": "682878",
      "system": "RxNorm",
      "display": "temsirolimus",
      "target": ["mTOR"],
      "indication": "RCC",
      "evidence_level": "FDA Approved"
    },
    "abemaciclib": {
      "code": "1946778",
      "system": "RxNorm",
      "display": "abemaciclib",
      "target": ["CDK4", "CDK6"],
      "indication": "HR+ breast cancer",
      "evidence_level": "FDA Approved"
    },
    "palbociclib": {
      "code": "1657851",
      "system": "RxNorm",
      "display": "palbociclib",
      "target": ["CDK4", "CDK6"],
      "indication": "HR+ breast cancer",
      "evidence_level": "FDA Approved"
    },
    "ribociclib": {
      "code": "1946779",
      "system": "RxNorm",
      "display": "ribociclib",
      "target": ["CDK4", "CDK6"],
      "indication": "HR+ breast cancer",
      "evidence_level": "FDA Approved"
    },
    "atezolizumab": {
      "code": "1792778",
      "system": "RxNorm",
      "display": "atezolizumab",
      "target": ["PD-L1"],
      "indication": "Various solid tumors",
      "evidence_level": "FDA Approved"
    },
    "durvalumab": {
      "code": "1946831",
      "system": "RxNorm",
      "display": "durvalumab",
      "target": ["PD-L1"],
      "indication": "NSCLC, urothelial cancer",
      "evidence_level": "FDA Approved"
    },
    "avelumab": {
      "code": "1946827",
      "system": "RxNorm",
      "display": "avelumab",
      "target": ["PD-L1"],
      "indication": "Merkel cell, urothelial cancer",
      "evidence_level": "FDA Approved"
    },
    "ipilimumab": {
      "code": "1094833",
      "system": "RxNorm",
      "display": "ipilimumab",
      "target": ["CTLA-4"],
      "indication": "Melanoma, RCC, CRC",
      "evidence_level": "FDA Approved"
    },
    "cemiplimab": {
      "code": "2177990",
      "system": "RxNorm",
      "display": "cemiplimab",
      "target": ["PD-1"],
      "indication": "Cutaneous squamous cell carcinoma",
      "evidence_level": "FDA Approved"
    },
    "dostarlimab": {
      "code": "2469246",
      "system": "RxNorm",
      "display": "dostarlimab",
      "target": ["PD-1"],
      "indication": "MSI-H/dMMR endometrial cancer",
      "evidence_level": "FDA Approved"
    },
    "talazoparib": {
      "code": "2177994",
      "system": "RxNorm",
      "display": "talazoparib",
      "target": ["PARP"],
      "indication": "BRCA-mutated breast cancer",
      "evidence_level": "FDA Approved"
    },
    "infigratinib": {
      "code": "2566082",
      "system": "RxNorm",
      "display": "infigratinib",
      "target": ["FGFR2"],
      "indication": "FGFR2 fusion/rearrangement cholangiocarcinoma",
      "evidence_level": "FDA Approved"
    },
    "pemigatinib": {
      "code": "2383306",
      "system": "RxNorm",
      "display": "pemigatinib",
      "target": ["FGFR1", "FGFR2", "FGFR3"],
      "indication": "FGFR2 fusion/rearrangement cholangiocarcinoma",
      "evidence_level": "FDA Approved"
    },
    "futibatinib": {
      "code": "2630235",
      "system": "RxNorm",
      "display": "futibatinib",
      "target": ["FGFR1", "FGFR2", "FGFR3", "FGFR4"],
      "indication": "FGFR2 fusion/rearrangement cholangiocarcinoma",
      "evidence_level": "FDA Approved"
    },
    "midostaurin": {
      "code": "1946837",
      "system": "RxNorm",
      "display": "midostaurin",
      "target": ["FLT3"],
      "indication": "FLT3-mutated AML",
      "evidence_level": "FDA Approved"
    },
    "gilteritinib": {
      "code": "2177995",
      "system": "RxNorm",
      "display": "gilteritinib",
      "target": ["FLT3"],
      "indication": "FLT3-mutated AML",
      "evidence_level": "FDA Approved"
    },
    "avapritinib": {
      "code": "2383305",
      "system": "RxNorm",
      "display": "avapritinib",
      "target": ["PDGFRA", "KIT"],
      "indication": "PDGFRA exon 18 mutant GIST",
      "evidence_level": "FDA Approved"
    },
    "ripretinib": {
      "code": "2469248",
      "system": "RxNorm",
      "display": "ripretinib",
      "target": ["KIT", "PDGFRA"],
      "indication": "Advanced GIST",
      "evidence_level": "FDA Approved"
    },
    "zanubrutinib": {
      "code": "2383307",
      "system": "RxNorm",
      "display": "zanubrutinib",
      "target": ["BTK"],
      "indication": "Mantle cell lymphoma, CLL",
      "evidence_level": "FDA Approved"
    },
    "acalabrutinib": {
      "code": "1946838",
      "system": "RxNorm",
      "display": "acalabrutinib",
      "target": ["BTK"],
      "indication": "CLL, mantle cell lymphoma",
      "evidence_level": "FDA Approved"
    },
    "ibrutinib": {
      "code": "1486436",
      "system": "RxNorm",
      "display": "ibrutinib",
      "target": ["BTK"],
      "indication": "CLL, MCL, WM",
      "evidence_level": "FDA Approved"
    },
    "venetoclax": {
      "code": "1856154",
      "system": "RxNorm",
      "display": "venetoclax",
      "target": ["BCL2"],
      "indication": "CLL, AML",
      "evidence_level": "FDA Approved"
    },
    "enasidenib": {
      "code": "1946840",
      "system": "RxNorm",
      "display": "enasidenib",
      "target": ["IDH2"],
      "indication": "IDH2-mutated AML",
      "evidence_level": "FDA Approved"
    },
    "ivosidenib": {
      "code": "2177996",
      "system": "RxNorm",
      "display": "ivosidenib",
      "target": ["IDH1"],
      "indication": "IDH1-mutated AML/cholangiocarcinoma",
      "evidence_level": "FDA Approved"
    }
  }
}
